Biotek-snakken — Februar 2020
-
3kroner- ja det var den tekniske side af sagen. Men fundamentalt har jeg utrolig svært ved at forstå hvad Nordic Nanovector laver på disse lave niveauer. De er godt i gang med fase 3. Resultaterne ser rigtig fine ud. Bivirkningsprofilen er god og Betalutin er let at administrere. Men de har jo haft noge forsinkelse tidl i patientrekuteringen. Så marked venter nok på at få bekræftet at alt går efter tidsplanen. Jeg ven
ter med tålmodighed. Jeg tror vi skal godt op i 2020. -
BLA filing with FDA targeted to 1H 2021
• Orphan Drug Designation granted in US and EU in 2014
• Enhanced dialogue with regulators to bring Betalutin
to FL patients quicker thanks to:
– Fast-track designation granted in the US in June 2018
– Promising Innovative Medicine (PIM) designation granted in the UK in October 2018 -
Photocure - https://abc7chicago.com/5944127/
-
Cantargia - pæn høj tegningskurs. https://cantargia.com/en/investors/rights-issue-2020?file=1
-
-
-
-
Tak, Aftenbakken. For os Orpha-investorer er der dog intet nyt i artiklen, som i øvrigt citerer en ugegammel Redeye-analyse. Men rart at der bliver skrevet om selskabet, så kendskabet bliver mere udbredt
-
Selv tak, sw1 - det var mere så man ved hvorfor bevægelsen i dag - er selv Orphanist:)
-
Test
-
Jeg har et frimærke i aktien. Best case kan det blive en Genmab-look a like.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind